论文部分内容阅读
目的:探讨EZH2蛋白在肾癌和肾癌细胞系中的表达情况及其与肾癌发生发展的关系。方法:应用Western blot检测12例肾癌和正常肾组织及两种细胞系ACHN和786-0中EZH2蛋白的表达,采用免疫组化法检测64例肾癌和12例正常肾组织中EZH2蛋白的表达情况,并分析与肾癌临床病理特征的关系。结果:Westernblot检测结果显示,EZH2蛋白在正常肾小管上皮细胞系HK 2的表达极低,而肾癌细胞系786-0和ACHN的表达水平较高;正常肾组织EZH2蛋白表达阴性,肾癌组织均有不同程度的表达,差异有统计学意义(P<0.05)。免疫组化结果示,肾癌和正常肾组织EZH2蛋白表达率分别为78.1%和16.7%,差异有统计学意义(P<0.01)。EZH2蛋白表达率在局限性和局部进展性肾癌分别为63.9%和92.9%,差异有统计学意义(P<0.01);EZH2蛋白表达率在肾癌不同病理分级组和是否淋巴结转移组间差异有统计学意义(P<0.05)。结论:EZH2异常表达与肾癌的分期、分级和淋巴结转移有关,与肾癌的临床进展关系密切。
Objective: To investigate the expression of EZH2 protein in renal cell carcinoma and renal cell carcinoma cell lines and its relationship with the development of renal cell carcinoma. Methods: Western blot was used to detect the expression of EZH2 protein in 12 cases of renal cell carcinoma and normal kidney tissues and two cell lines ACHN and 786-0. Immunohistochemistry was used to detect the expression of EZH2 protein in 64 cases of renal cell carcinoma and 12 cases of normal renal tissues Expression, and analyze the relationship with the clinicopathological features of renal cell carcinoma. Results: The results of Western blot showed that the expression of EZH2 protein was very low in normal renal tubular epithelial cell line HK 2, while the expression of renal cell carcinoma cell line 786-0 and ACHN was higher. The expression of EZH2 protein in normal renal tissue was negative, There are different degrees of expression, the difference was statistically significant (P <0.05). Immunohistochemistry showed that the expression rates of EZH2 protein in renal cell carcinoma and normal renal tissues were 78.1% and 16.7%, respectively, with statistical significance (P <0.01). The positive rate of EZH2 protein expression was 63.9% and 92.9% in the localized and locally advanced renal cell carcinoma patients (P <0.01). The positive rate of EZH2 protein expression in different pathological grades of renal cell carcinoma and lymph node metastasis There was statistical significance (P <0.05). Conclusion: The abnormal expression of EZH2 is associated with the stage, grade and lymph node metastasis of renal cell carcinoma, which is closely related to the clinical progress of renal cell carcinoma.